Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors

Cancer

Volumn 117, Issue 19, 2011, Pages 4475-4483

  Uchino, Koji ^a   Tateishi, Ryosuke ^a   Shiina, Shuichiro ^a   Kanda, Miho ^b   Masuzaki, Ryota ^a   Kondo, Yuji ^a   Goto, Tadashi ^a   Omata, Masao ^c   Yoshida, Haruhiko ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Kyoundo Hospital   (Japan)

^c YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

clinical course; extrahepatic metastasis; hepatocellular carcinoma; prognosis

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; FLUOROURACIL; INTERFERON; ORANTINIB; TS 1; UNCLASSIFIED DRUG;

ADRENAL METASTASIS; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER CLASSIFICATION; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH CLASSIFICATION; DISEASE COURSE; EXTRAHEPATIC METASTASIS; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; SCORING SYSTEM; SPLEEN METASTASIS; SURVIVAL RATE; TUMOR ABLATION; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BRACHYTHERAPY; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80052927028     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25960     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108. (Pubitemid 40372904)
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T,. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol. 2009; 39: 850-858.
3. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology. 1995; 22 (4 pt 1): 1027-1033.
4. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56: 918-928. (Pubitemid 15228292)
5. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000; 32: 1224-1229.
6. Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol. 1993; 160: 1023-1028. (Pubitemid 23141242)
7. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1739. (Pubitemid 34607087)
8. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005; 129: 122-130. (Pubitemid 41002049)
9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-699. (Pubitemid 26079803)
10. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL,. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000; 216: 698-703. (Pubitemid 30660840)
11. Kanda M, Tateishi R, Yoshida H, et al. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int. 2008; 28: 1256-1263.
12. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236. (Pubitemid 43112690)
13. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-1917. (Pubitemid 37518510)
14. Burroughs A, Hochhauser D, Meyer T,. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004; 5: 409-418. (Pubitemid 38878044)
15. Nowak AK, Chow PK, Findlay M,. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004; 40: 1474-1484. (Pubitemid 38757734)
16. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
17. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
18. Torzilli G, Minagawa M, Takayama T, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology. 1999; 30: 889-893. (Pubitemid 29458276)
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
20. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60.
21. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655. (Pubitemid 13149996)
22. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA,. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984; 3: 143-152. (Pubitemid 14052973)
23. Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996; 111: 720-726. (Pubitemid 26293238)
24. Ishii H, Furuse J, Kinoshita T, et al. Extrahepatic spread from hepatocellular carcinoma: who are candidates for aggressive anti-cancer treatment? Jpn J Clin Oncol. 2004; 34: 733-739. (Pubitemid 41615270)
25. Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007; 13: 414-420. (Pubitemid 46178976)
26. Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007; 141: 196-202. (Pubitemid 46149871)
27. Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol. 2005; 20: 1781-1787. (Pubitemid 43961087)
28. Okusaka T, Okada S, Ishii H, et al. Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology. 1997; 44: 251-257. (Pubitemid 27096048)
29. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005; 103: 1201-1209. (Pubitemid 40328091)
30. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006; 131: 461-469. (Pubitemid 44142456)
31. Obi S, Yoshida H, Toune R, et al. Combination therapy of intra-arterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006; 106: 1990-1997. (Pubitemid 43673215)
32. Lam CM, Lo CM, Yuen WK, Liu CL, Fan ST,. Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma. Br J Surg. 1998; 85: 1198-1200.
33. Park JS, Yoon DS, Kim KS, et al. What is the best treatment modality for adrenal metastasis from hepatocellular carcinoma? J Surg Oncol. 2007; 96: 32-36.
34. Une Y, Misawa K, Shimamura T, et al. Treatment of lymph node recurrence in patients with hepatocellular carcinoma. Surg Today. 1994; 24: 606-609. (Pubitemid 24229306)
35. Momoi H, Shimahara Y, Terajima H, et al. Management of adrenal metastasis from hepatocellular carcinoma. Surg Today. 2002; 32: 1035-1041. (Pubitemid 36216438)
36. Poon RT, Fan ST, O'Suilleabhain CB, Wong J,. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg. 2002; 195: 311-318. (Pubitemid 35006284)
37. Kaizu T, Karasawa K, Tanaka Y, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol. 1998; 93: 2167-2171. (Pubitemid 29076869)
38. Park YJ, Lim do H, Paik SW, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol. 2006; 41: 1099-1106. (Pubitemid 44896725)
39. Chang L, Chen YL, Kao MC,. Intracranial metastasis of hepatocellular carcinoma: review of 45 cases. Surg Neurol. 2004; 62: 172-177. (Pubitemid 38917099)
40. Zeng ZC, Tang ZY, Fan J, et al. Radiation therapy for adrenal gland metastases from hepatocellular carcinoma. Jpn J Clin Oncol. 2005; 35: 61-67. (Pubitemid 40567870)
41. Yamakado K, Anai H, Takaki H, et al. Adrenal metastasis from hepatocellular carcinoma: radiofrequency ablation combined with adrenal arterial chemoembolization in 6 patients. AJR Am J Roentgenol. 2009; 192: W300-W305.
42. Kuehl H, Stattaus J, Forsting M, Antoch G,. Transhepatic CT-guided radiofrequency ablation of adrenal metastases from hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2008; 31: 1210-1214.
43. Kashima M, Yamakado K, Takaki H, et al. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol. 2010; 194: 536-541.